argenx SE (NAS:ARGX)
$ 356.01 -3.47 (-0.97%) Market Cap: 21.22 Bil Enterprise Value: 18.74 Bil PE Ratio: 0 PB Ratio: 5.39 GF Score: 74/100

argenx SE - Special Call Transcript

Feb 01, 2021 / 01:30PM GMT
Release Date Price: $317.4 (+8.32%)
Operator

Good morning. My name is Elissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the argenx Conference Call. (Operator Instructions)

Thank you. Beth DelGiacco, Vice President of Investor Relations and Corporate Communications, you may begin your conference.

Beth DelGiacco
argenx SE - VP of IR

Thanks, Elissa. A press release was issued earlier today announcing our decision to continue the ADHERE trial of efgartigimod for the treatment of chronic inflammatory demyelinating polyneuropathy, or CIDP, following an interim analysis and confirmation by an independent data monitoring committee. The press release can be found on our website along with the presentation for today's webcast.

Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot